MRSN Mersana Therapeutics Inc Earnings per share for the last twelve months

Official company branding of Mersana (MRSN)

Risks for Mersana Therapeutics (MRSN) are linked to the instability of global raw material supplies and the complexities of protecting patents abroad. The rolling 12-month earnings per share visualizes management efficiency, while -14.15 reflects the latest value of the metric. Growth is driven by the development of the Dolasynthen platform and partnerships with industry behemoths, while plant readiness ensures the rapid scaling of mass drug production.

MRSN (Mersana Therapeutics) Net earnings per one share for the last twelve months history from 07/04/2022 to 01/17/2026

MRSN (Mersana): analytical breakdowns and indicator data

- current quotes and average value forecast:
Basic company analysis:MRSN - Mersana
Mass-produced product of Mersana Therapeutics Inc

Mersana Therapeutics (MRSN) leverages AI to automate the synthesis of oncology drugs, yet the cost of clinical trials places a significant strain on capital. This metric calculates the net income allocated per common share over a rolling year. It enables an assessment of real business efficiency by excluding the impact of share issuance. It is critical for investors to see the company's ability to generate income against high expenditures. A negative trend in the 12-month rolling income per share signals a risk of asset devaluation.